The global intravascular stents market accounted for USD 13.41 billion in 2023 and is expected to reach USD 31.39 billion by 2034 with a CAGR of 8.04% during the forecast period 2024-2034. The market will grow as a result of factors such as the growing geriatric population, rising prevalence of cardiovascular illnesses, rising use of minimally invasive procedures, and developments in stent technology.
The World Health Organization (WHO) states that the greatest cause of death worldwide is cardiovascular illnesses, or CVDs. Atherosclerosis, a disorder where plaque buildup narrows arteries, is a major risk factor for CVD. Patients with CVD can benefit from improved blood flow and blocked artery openings thanks to intravascular stents. Intravascular stent demand is predicted to increase in line with the growing frequency of cardiovascular diseases (CVDs), which is attributed to reasons such as aging populations, poor lifestyles, and rising rates of obesity and diabetes. For instance, Boston Scientific Corporation announced in February 2023 that the FDA had approved EluviaTM DES, a device with novel polymer technology intended to lower long-term problems.
By type, the drug-eluting stents (DES) segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the superior efficacy in reducing restenosis rates and minimizing the need for repeat interventions compared to bare-metal stents (BMS) and other alternatives. For instance, Medtronic plc received CE Mark clearance for the Resolute OnyxTM DES, which has a novel biocompatible covering intended to promote healing, on October 26, 2023. Additionally, the bioabsorbable stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the potential to mitigate long-term complications associated with permanent implants, such as late stent thrombosis and vessel recoil, along with their ability to gradually dissolve, restoring natural vessel function.
By mode of delivery, the balloon-expandable stents segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the precision in deployment, effective vessel scaffolding, and compatibility with various lesion types, leading to widespread adoption, particularly in complex coronary interventions. For instance, Terumo Corporation introduced the new SafeSlip hydrophilic angiographic catheter on April 12, 2023, which may help to lessen vascular spasms during stent treatments. Additionally, the self-expanding stents segment is estimated to grow at the fastest CAGR during the forecast period owing to the ease of deployment in challenging anatomies, reduced risk of stent malapposition, and broader applicability in peripheral vascular interventions.
By product, the coronary stents segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the high prevalence of coronary artery disease (CAD) and the extensive use of stenting procedures for coronary revascularization, driving demand for coronary stents. For instance, on May 23, 2023, Biotronik SE & Co. KG presented encouraging results from the BIOFLOW-V study, demonstrating the long-term safety and effectiveness of their OrbiTM DES in coronary arteries with tiny vessels. Additionally, the peripheral stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of peripheral artery disease (PAD), expanding applications of stents in peripheral vascular interventions, and advancements in stent technology tailored for peripheral indications.
By end-user, the hospitals & cardiac centers segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the high volume of interventional procedures performed in these facilities, along with their state-of-the-art infrastructure and specialized expertise in cardiovascular care. For instance, Cardinal Health, Inc. strengthened its position in the angiographic catheter and interventional device market in May 2023 by announcing the acquisition of Merit Medical Systems, indirectly supporting intravascular stent treatments. Additionally, the ambulatory surgical centers segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient cardiovascular procedures, increasing emphasis on cost-effective healthcare delivery, and expanding availability of advanced interventional technologies in ambulatory settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, widespread adoption of advanced medical technologies, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of cardiovascular diseases, growing adoption of minimally invasive procedures, and rising healthcare expenditure in the Asia Pacific region. For instance, Medtronic plc gained FDA approval for the Onyx Frontier DES in May 2022. This cutting-edge stent from the Resolute DES family has the same cutting-edge stent platform as the Resolute Onyx DES, but it also has a unique distribution system that is intended to improve acute performance, especially in difficult instances.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The World Health Organization (WHO) states that the greatest cause of death worldwide is cardiovascular illnesses, or CVDs. Atherosclerosis, a disorder where plaque buildup narrows arteries, is a major risk factor for CVD. Patients with CVD can benefit from improved blood flow and blocked artery openings thanks to intravascular stents. Intravascular stent demand is predicted to increase in line with the growing frequency of cardiovascular diseases (CVDs), which is attributed to reasons such as aging populations, poor lifestyles, and rising rates of obesity and diabetes. For instance, Boston Scientific Corporation announced in February 2023 that the FDA had approved EluviaTM DES, a device with novel polymer technology intended to lower long-term problems.
By type, the drug-eluting stents (DES) segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the superior efficacy in reducing restenosis rates and minimizing the need for repeat interventions compared to bare-metal stents (BMS) and other alternatives. For instance, Medtronic plc received CE Mark clearance for the Resolute OnyxTM DES, which has a novel biocompatible covering intended to promote healing, on October 26, 2023. Additionally, the bioabsorbable stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the potential to mitigate long-term complications associated with permanent implants, such as late stent thrombosis and vessel recoil, along with their ability to gradually dissolve, restoring natural vessel function.
By mode of delivery, the balloon-expandable stents segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the precision in deployment, effective vessel scaffolding, and compatibility with various lesion types, leading to widespread adoption, particularly in complex coronary interventions. For instance, Terumo Corporation introduced the new SafeSlip hydrophilic angiographic catheter on April 12, 2023, which may help to lessen vascular spasms during stent treatments. Additionally, the self-expanding stents segment is estimated to grow at the fastest CAGR during the forecast period owing to the ease of deployment in challenging anatomies, reduced risk of stent malapposition, and broader applicability in peripheral vascular interventions.
By product, the coronary stents segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the high prevalence of coronary artery disease (CAD) and the extensive use of stenting procedures for coronary revascularization, driving demand for coronary stents. For instance, on May 23, 2023, Biotronik SE & Co. KG presented encouraging results from the BIOFLOW-V study, demonstrating the long-term safety and effectiveness of their OrbiTM DES in coronary arteries with tiny vessels. Additionally, the peripheral stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of peripheral artery disease (PAD), expanding applications of stents in peripheral vascular interventions, and advancements in stent technology tailored for peripheral indications.
By end-user, the hospitals & cardiac centers segment accounted for the highest revenue-grossing segment in the global intravascular stents market in 2023 owing to the high volume of interventional procedures performed in these facilities, along with their state-of-the-art infrastructure and specialized expertise in cardiovascular care. For instance, Cardinal Health, Inc. strengthened its position in the angiographic catheter and interventional device market in May 2023 by announcing the acquisition of Merit Medical Systems, indirectly supporting intravascular stent treatments. Additionally, the ambulatory surgical centers segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient cardiovascular procedures, increasing emphasis on cost-effective healthcare delivery, and expanding availability of advanced interventional technologies in ambulatory settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, widespread adoption of advanced medical technologies, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of cardiovascular diseases, growing adoption of minimally invasive procedures, and rising healthcare expenditure in the Asia Pacific region. For instance, Medtronic plc gained FDA approval for the Onyx Frontier DES in May 2022. This cutting-edge stent from the Resolute DES family has the same cutting-edge stent platform as the Resolute Onyx DES, but it also has a unique distribution system that is intended to improve acute performance, especially in difficult instances.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Mode of Delivery, Product, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Intravascular Stents Market Report 2023 - 2034
Intravascular Stents Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Drug Eluting Stents (DES)
- Bare Metal Stents (BMS)
- Bioabsorbable Stents
Intravascular Stents Market Analysis & Forecast by Mode of Delivery 2023 - 2034 (Revenue USD Bn)
- Self-expanding Stents
- Balloon-expandable Stents
Intravascular Stents Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Coronary Stents
- Peripheral Stents
- Iliac Artery Stents
- Femoral Artery Stents
- Carotid Artery Stents
- Renal Artery Stents
- Other Peripheral Stents
- Neurovascular Stents
- Intracranial Stents
- Flow Diverters
- Hospitals & Cardiac Centers
- Ambulatory Surgical Centers
- Others
Intravascular Stents Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Intravascular Stents Market: Type Estimates & Trend Analysis
8. Intravascular Stents Market: Mode of Delivery Estimates & Trend Analysis
9. Intravascular Stents Market: Product Estimates & Trend Analysis
10. Intravascular Stents Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Intravascular Stents Market
13. Europe Global Intravascular Stents Market
14. Asia Pacific Global Intravascular Stents Market
15. Latin America Global Intravascular Stents Market
16. MEA Global Intravascular Stents Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Cook Medical Inc.
- Cardinal Health Inc.
- C. R. Bard Inc. (acquired by BD)
- MicroPort Scientific Corporation
- Meril Life Sciences Pvt. Ltd.
- Stentys SA
- Vascular Concepts (India) Pvt. Ltd.
- Translumina GmbH
- OrbusNeich Medical Company Limited
